Cargando…

The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab

(1) Background: The use of virtual reality (VR) in improving patient comfort related to medical procedures in oncology patients raised the question of whether similar benefits could be obtained by patients with inflammatory bowel disease (IBD). (2) Methods: In this prospective, randomized, controlle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewandowski, Konrad, Kaniewska, Magdalena, Rosołowski, Mariusz, Kucha, Piotr, Rydzewska, Grażyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235083/ https://www.ncbi.nlm.nih.gov/pubmed/34205323 http://dx.doi.org/10.3390/jcm10122709

Ejemplares similares

The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome
por: Lewandowski, Konrad, et al.
Publicado: (2022)

Gastrointestinal symptoms in COVID-19
por: Lewandowski, Konrad, et al.
Publicado: (2022)

Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) – friend or foe?
por: Lewandowski, Konrad, et al.
Publicado: (2021)

Selected Aspects of Nutrition in the Prevention and Treatment of Inflammatory Bowel Disease
por: Panufnik, Paulina, et al.
Publicado: (2022)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

Low-FODMAP Diet for the Management of Irritable Bowel Syndrome in Remission of IBD
por: Więcek, Martyna, et al.
Publicado: (2022)

Long-lasting dyspeptic symptoms – another consequence of the COVID-19 pandemic?
por: Nazarewska, Anna, et al.
Publicado: (2023)

Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything?
por: Lewandowski, Konrad, et al.
Publicado: (2023)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Bone Metabolism Alteration in Patients with Inflammatory Bowel Disease
por: Tulewicz-Marti, Edyta Maria, et al.
Publicado: (2022)

Skin and gastrointestinal symptoms in COVID-19
por: Ciechanowicz, Piotr, et al.
Publicado: (2020)

The introduction of the IBD Disk in Poland – a new tool for assessing disability in patients with inflammatory bowel disease
por: Eder, Piotr, et al.
Publicado: (2019)

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
por: Szczubełek, Martyna, et al.
Publicado: (2021)

Reply to van Lingen et al. Comment on “Szczubełek et al. Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients. Nutrients 2021, 13, 4112”
por: Szczubełek, Martyna, et al.
Publicado: (2022)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group Recommendations
por: Kaniewska, Magdalena, et al.
Publicado: (2014)

Management of anaemia in patients with inflammatory bowel disease – results of a questionnaire among Polish healthcare professionals
por: Tulewicz-Marti, Edyta M., et al.
Publicado: (2021)

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
por: Abraham, Bincy P., et al.
Publicado: (2023)

The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Awareness and Compliance with the Recommendations of Primary and Secondary Prevention of Cancer in Patients with Inflammatory Bowel Disease
por: Tulewicz-Marti, Edyta, et al.
Publicado: (2023)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
por: Luzentales-Simpson, Matthew, et al.
Publicado: (2021)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Biomarkers in management of inflammatory bowel disease
por: Moniuszko, Andrzej, et al.
Publicado: (2013)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

Assessment of sexual dysfunction in patients with inflammatory bowel disease
por: Szydlarska, Dorota, et al.
Publicado: (2019)

New pharmaceuticals in inflammatory bowel disease
por: Łodyga, Michał, et al.
Publicado: (2015)

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience
por: Erdoğan, Çağdaş, et al.
Publicado: (2022)

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kbb9vl09q6mq63nkefhck1kpar